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T

he myelin sheath forms by the spiral wrapping of a
glial membrane around the axon. The mechanisms
responsible for this process are unknown but are
likely to involve coordinated changes in the glial cell cytoskeleton. We have found that inhibition of myosin II, a key
regulator of actin cytoskeleton dynamics, has remarkably
opposite effects on myelin formation by Schwann cells
(SC) and oligodendrocytes (OL). Myosin II is necessary for
initial interactions between SC and axons, and its inhibition or down-regulation impairs their ability to segregate

axons and elongate along them, preventing the formation
of a 1:1 relationship, which is critical for peripheral
nervous system myelination. In contrast, OL branching, differentiation, and myelin formation are potentiated by inhibition of myosin II. Thus, by controlling the spatial and
localized activation of actin polymerization, myosin II regulates SC polarization and OL branching, and by extension
their ability to form myelin. Our data indicate that the
mechanisms regulating myelination in the peripheral and
central nervous systems are distinct.

Introduction
Myelin is a highly specialized membrane that wraps around
axons in the peripheral (PNS) and central (CNS) nervous systems.
Although the function of myelin in facilitating the efficient and
rapid propagation of nerve impulses by saltatory conduction has
long been known, the basic mechanisms that drive the extension
and wrapping of the glial membrane around the axon remain
poorly understood. During their development and differentiation into myelin-forming cells, oligodendrocytes (OL) in the
CNS and Schwann cells (SC) in the PNS undergo striking morphological changes that involve the active remodeling of their
cytoskeleton. Data from multiple studies have underscored the
importance of the actin cytoskeleton in process extension and
myelination by both SC and OL (Fernandez-Valle et al., 1997;
Kim et al., 2006; Bacon et al., 2007).
SC and OL express several regulatory actin-binding proteins, which regulate actin polymerization and process formaH. Wang and A. Tewari contributed equally to this paper.
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tion (Bacon et al., 2007). Pharmacological inhibition of actin
polymerization has a negative effect on process extension,
axonal ensheathment, differentiation, and myelination by both
SC and OL (Fernandez-Valle et al., 1997; Bacon et al., 2007).
Similarly, mice lacking WAVE1, an actin-binding protein important for lamellipodia formation, show defective OL morphogenesis and regional hypomyelination (Kim et al., 2006). Despite
the fact that myelin formation by glial cells appears to involve the
assembly and progression of an inner mesaxon around one (SC)
or several (OL) axons (Bunge et al., 1989), the question still
remains as to whether or not this process is driven by a common
actin-polymerization mechanism and whether this is regulated
in a similar fashion in the CNS and the PNS. Significantly, several
studies have shown that members of the small Rho-GTPase family,
the main regulators of actin cytoskeleton dynamics, are also important for coordinating the formation and maintenance of the
myelin sheath by SC and OL. Activation of Rac1 downstream
of ␤1 integrin signaling has been implicated in process extension and axonal segregation and myelination by SC (Benninger
et al., 2007; Nodari et al., 2007). In contrast, in the CNS, Rac1
© 2008 Wang et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the ﬁrst six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license,
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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and Cdc42, although dispensable for OL differentiation and
myelination, appear to be important for myelin maintenance and
stability (Thurnherr et al., 2006). Although the role of Rho in
myelination has not been evaluated directly, constitutive activation of Rho interferes with OL branching and maturation (Wolf
et al., 2001; Liang et al., 2004), whereas its inactivation promotes
plasma membrane condensation and differentiation in Oligneu cells (Kippert et al., 2007). In the PNS, inactivation of Rhoassociated kinase (ROCK), a major downstream effector of Rho,
does not prevent SC differentiation and myelination but results
in aberrant myelin organization (Melendez-Vasquez et al., 2004).
Collectively, these contrasting effects of small GTPases function
in myelinating glial cells suggest that the mechanisms controlling actin dynamics in SC and OL during differentiation and myelination are regulated differently.
The spatial and temporal regulation of actin interactions
with specific binding proteins and myosin motors provides a mechanism for precisely regulating actin assembly and dynamics in a
variety of higher-order cellular structures (Chhabra and Higgs,
2007). In nonmuscle cells, phosphorylation of the regulatory
chain of the motor protein myosin II (MLC2) by ROCK is a key
regulator of actomyosin assembly (Conti and Adelstein, 2008).
We have previously found that MLC2 phosphorylation is dramatically up-regulated at the onset of PNS myelination, and that
inhibition of ROCK in myelinating cocultures results in a dramatic decrease of phosphorylated MLC2 levels and abnormal SC
myelination (Melendez-Vasquez et al., 2004). Using a combination of pharmacological and molecular tools, we have further investigated the specific role of myosin II during myelin formation
by both SC and OL. We have found in this paper that myelination in the PNS and CNS is differentially regulated by myosin II.
Myosin II is necessary for SC differentiation and myelination.
In contrast, inhibition of myosin II activity in OL precursors does
not interfere with their differentiation or their ability to form myelin but instead potentiates myelin formation in culture. Our results
indicate that the mechanisms regulating glial cell cytoskeleton
and myelin formation in the PNS and CNS are distinct.

Results
Inhibition of myosin II activity reduces the
number and size of SC myelin segments

To study the role of myosin II in myelination, we first examined
the effects of blebbistatin, a specific inhibitor of nonmuscle
myosin II (Straight et al., 2003), in SC neuronal cocultures. SC
were added to established dorsal root ganglion (DRG) neuron
cultures with extensive neurite outgrowth. Cocultures were then
switched to media containing ascorbate to promote basal lamina
formation and myelination, with or without blebbistatin (1, 5,
10, 25, and 50 μM). As an additional control, some cultures
were treated with an inactive enantiomer of blebbistatin at the
same concentration (Fig. 1 A). Blebbistatin was well tolerated
for the duration of the experiment, without any significant effect
on SC survival as measured by a TUNEL assay (unpublished
data). After an additional 2–3 wk, cultures were fixed and
stained for myelin basic protein (MBP) to identify compact myelin sheaths.
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The most striking and reproducible effect of blebbistatin
was a reduction in the number and size of MBP+ segments that
formed in cocultures (Fig. 1, A and C). These effects were
dose-dependent, and at the highest dose used (50 μM), myelination was completely abolished (Fig. 1 C). Because blebbistatin can interfere with cytokinesis and cell division (Straight
et al., 2003), we examined the effects of the drug on SC proliferation and survival in the cocultures. There was no effect
on cell survival based on the TUNEL assay but a small decrease in the index of BrdU incorporation between control and
treated cultures was observed only at the highest doses of the
drug (from 30% in control cultures to 20–24% in cultures
treated with blebbistatin at 25 or 50 μM; see Table S1, available at http://www.jcb.org/cgi/content/full/jcb.200802091/DC1).
Despite reduced proliferation, myelination could not be rescued in blebbistatin-treated cultures (at 10, 25, and 50 μM)
even when an excess of SC (106 instead of 105) were added
to the cultures (unpublished data). Furthermore, cocultures
treated with blebbistatin for 3–7 d and then maintained for additional 1–2 wk without the drug showed normal myelination,
which indicates that the effects of the drug are reversible.
Thus, we conclude that the inhibition of myelination in these
cultures was not caused by insufficient SC numbers or an effect on cell viability.
We also found that the addition of blebbistatin during the
first 24–72 h after switching the cultures to ascorbate-containing
media had a more powerful effect in inhibiting myelination (unpublished data). Adding blebbistatin to cultures 4 or 7 d after
myelin induction had no apparent effect on myelin formation.
These results indicate that myosin II activity is critical at early
stages of myelination. Closer examination of SC morphology
in blebbistatin-treated cultures revealed several abnormalities:
SC nuclei were round in shape and did not elongate along the
axons (Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200802091/DC1). Even among those cells that formed myelin, the nuclei appeared round and were asymmetrically localized along the internode, in contrast to the elongated and
centered nuclei characteristic of myelinating SC in control cultures (Fig. 1 B). Although segments in blebbistatin-treated cultures
were shorter than controls (P < 0.0001; Fig. 1 C), they appeared
to be of normal thickness. Costaining with antibodies to laminin
and sodium channels (Fig. S2) also revealed that some SC in
blebbistatin-treated cultures form multiple short segments, akin to
the defects previously described after ROCK inhibition (MelendezVasquez et al., 2004).
The reduction in myelin formation was corroborated by
significantly decreased amounts of myelin proteins (MBP, P0,
and myelin-associated glycoprotein) and transcription factors (Krox-20 and Oct6) based on Western blotting (Fig. 1 D).
Basal lamina components such as laminin chains ␣2 and ␥1/␤1
were also reduced. Electron microscopy analysis of blebbistatin-treated cultures further confirmed that SC appeared
to be arrested at the premyelinating stage and were unable
to properly ensheath and segregate axons (Fig. 1 E). Many
large-diameter naked axons were seen in these cultures, and in
some cases, they were segregated but remained unmyelinated
(Fig. 1 F). The basal lamina around the SC appeared thin and patchy

Figure 1. Inhibition of myelination in SC cocultures
treated with blebbistatin. (A) 2-wk-old myelinating SC
neuronal cocultures stained for MBP, Krox-20, and
neuroﬁlament. A signiﬁcant reduction in myelin formation and Krox-20 expression was observed in cultures
treated with the active (⫺) blebbistatin enantiomer
compared with control cultures and cultures treated
with the inactive (+) enantiomer. (B) Myelinated segments formed in blebbistatin (⫺)-treated cultures
(right) were shorter than in control cultures (left) and
frequently exhibited rounded and off-centered SC nuclei (asterisks). (C) Quantitation of internode length
and number in 2-wk-old cocultures. A dose-dependent
reduction in both the total number (n) and the length
of the myelinated segments was consistently observed
in treated cultures compared with the control. At the
highest dose of blebbistatin (50 μM), myelination
was completely abolished. Data in the graph represent mean ± SEM from two independent experiments
(two cultures per condition per experiment). ***, P <
0.0001. (D) Western blots from 2-wk-old cocultures,
which conﬁrm a signiﬁcant reduction in the expression of myelin proteins, transcription factors, and laminin chains in blebbistatin-treated cultures (T). Actin
and Tau levels were comparable in both treated and
control cultures. (E and F) Ultrastructural analysis of
18-d-old myelinating cocultures treated with 25 μM
blebbistatin showing abnormalities in axon ensheathing and segregation. (E) An SC on top of a bundle
of axons appears arrested at a premyelinating stage.
Many axons (asterisks) are surrounded by very short
cytoplasmic processes (black arrowheads), which fail
to completely wrap or segregate them in a 1:1 association. Rough endoplasmic reticulum (red arrowheads)
is very prominent in this cell. (F) A large segregated
but nonmyelinated axon (ax), which is also contacted
by a process (red asterisk) derived from a different
SC. Many large-diameter naked axons are also observed in this ﬁeld (black asterisks). The arrowhead
points to a very short cytoplasmic process failing
to surround an axon. Bars: (A) 100 μm; (B) 25 μm;
(E and F) 1 μm.

(not depicted), and they also exhibited abnormal branching
and process extension. No obvious changes on the density/
morphology of axons (Fig. 1 A) or in the levels of axonalspecific proteins such as Tau (Fig. 1 D) were observed between control and treated cultures. Collectively, these results
suggest that myosin II inhibition greatly impairs differentiation and myelination by SC in culture.

Myosin II is required for normal SC
interactions with axons and myelination

To confirm that the myelination defects observed in blebbistatin-treated cocultures were caused by inhibition of myosin II
activity in SC and not by an effect of the drug on neurons, primary SC cultures were infected with lentivirus-expressing short
hairpin RNA (shRNA) targeting the regulatory (light) chain of
REGULATION OF MYELINATION BY MYOSIN II • Wang et al.
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Figure 2. Knockdown of myosin II by shRNA results in abnormal SC morphology and prevents proper interactions with axons and myelination. (A) SC
infected with lentivirus expressing shRNA against the regulatory chain of myosin II (shMLC) or a scrambled nontargeting sequence (shSCR) were seeded
onto puriﬁed DRG neurons and allowed to myelinate. After 18 d, cocultures were stained for MBP and neuroﬁlament. A clear reduction in the amount
of myelin formed in cocultures by SC expressing shMLC compared with those expressing nontargeting (SCR) shRNA was consistently observed. (B, left)
Validation of protein knockdown in SC cultures. Western blots from control noninfected SC cultures (NI) and cultures infected with either vector alone (V)
or vectors expressing targeting (MLC) and nontargeting (SCR) shRNA showing a marked reduction in the levels of phosphorylated MLC, total MLC, and
both isoforms of myosin II only in SC cultures infected with lentivirus shMLC. (right) Western blots of myelinating cocultures showing a marked reduction in
the total amount of myelin proteins (P0 and MBP) in cocultures established with SC infected with shMLC. Control for vector expression (GFP) and protein
loading (actin) are also shown. (C) Quantitation of MBP+ segment number and length formed in 18-d-old myelinating cocultures by SC infected with shMLC
compared with nontargeting control (shSCR). Data represent mean ± SEM from two independent experiments (three cultures per condition per experiment).
(D) 5-d-old cocultures stained for GFP to visualize infected SCs and also for neuroﬁlament and laminin ␣2. SC expressing MLC shRNA have round nuclei
and extend multiple long and thin processes. Knockdown cultures also showed a marked reduction in the expression of laminin ␣2 chain and impaired
basal lamina assembly. In control cultures (shSCR), SC exhibited the characteristic elongated morphology upon contact with the axons. (E) Detail of an SC
expressing shMLC-GFP in coculture with axons (blue). The cell has multiple processes, some of which appear to contact axons (asterisks), whereas others
fail to do so (arrowheads). Bars: (A) 100 μm; (D) 100 μm; (E) 20 μm.

myosin II (hence called MLC2). Phosphorylation of MLC2
activates the motor activity of myosin II and is required for
assembly of myosin II heavy chains (Bresnick, 1999). As controls,
SC cultures were infected with the empty lentiviral vector
(pLL3.7) or nontargeting (scrambled) lentivirus (shSCR). Western blotting confirmed a significant and specific reduction in the
amount of MLC2, phospho-MLC2, and both myosin IIA and
IIB in SC infected with two different constructs expressing
shMLC2 used separately (not depicted) or in combination (Fig. 2 B,
left). Infected SC were then seeded onto DRG neuronal cultures
and kept under myelinating conditions for 2–3 wk. In agreement
1174
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with our inhibitor data, the amount of myelin formed in cultures
established with myosin-deficient SC was significantly reduced
(Fig. 2 A). Western blotting also confirmed a decrease in the
amount of myelin proteins (MBP and P0) expressed in knockdown cultures (Fig. 2 B, right). Quantitation of the number and
length of MBP+ segments (Fig. 2 C) showed that in the absence
of MLC2, the number of MBP+ segments per field was significantly reduced (P < 0.001) and were on average 30% shorter
than controls (P < 0.001).
Myosin-deficient SC exhibited a morphology akin to that
observed in blebbistatin-treated cultures with rounded nuclei

Figure 3. Myosin II regulates actin protrusive
activity and is necessary to establish proper
SC polarity. Subconﬂuent SC cultures stained
with phalloidin and antibodies to N-cadherin,
MLC, and vinculin. (A and B) In control cultures, SC display abundant cortical actin and
stress ﬁbers (dotted line). MLC staining is also
found at stress ﬁbers (insets 1 and 3) but not
at focal adhesions (arrowheads, inset 3). (B)
Two randomly polarized (front-to-back) SC
showing concentration of N-cadherin staining
in actin-rich protrusions at the leading edge
(arrowheads) and also at the tip of the cell tail
(asterisks, inset 2). Accumulation of MLC is observed at the retracting tail (inset 2), where it
colocalizes with vinculin (inset 4). (C and D)
SC treated with blebbistatin (25 μM for 60 min)
display striking changes in the organization of
the actin cytoskeleton, including loss of stress
ﬁbers and the formation of multiple actin
spikes throughout the entire cell body, where
N-cadherin is highly concentrated (arrowheads).
Many long and very thin cell processes (asterisks) are also observed in treated cultures.
(E–H) SC-DRG cocultures maintained for 3 d in
myelin-promoting media with or without blebbistatin and stained for N-cadherin, neuroﬁlament, and Hoechst nuclear staining. In control
conditions (E and F), SCs that are starting to
elongate (asterisks) show a “track-like” pattern
of N-cadherin staining along the axons they
contact (broken line). In blebbistatin-treated
cultures (G and H), multipolar SCs (asterisks)
extend many N-cadherin–positive processes
toward various axons. Staining in these processes at the SC–axon interface (dotted line)
does not show the track-like pattern found in
controls. Arrowheads indicate processes with
patchy N-cadherin staining that do not align
with any axon in the ﬁeld. Bars, 10 μm.

and multiple long and thin processes that failed to properly
elongate along axons (Fig. 2, D and E). In addition, defects in
␣2 laminin expression and basal lamina organization were also
observed (Fig. 2 D). Collectively, these data suggest that knockdown of myosin II in SC impairs their ability to properly polarize, associate with axons, and myelinate.
Myosin II regulates localized actin
protrusive activity and is necessary
to establish proper SC polarity and
contact with the axon

Several studies have demonstrated a direct role of myosin II in
the control of cell polarity and localized actin-protrusive activity, which are essential for directed migration (Lo et al., 2004;
Even-Ram et al., 2007). To further evaluate the effects of myosin II inhibition on SC morphology and polarity, we analyzed
the changes in actin cytoskeleton and actin-associated proteins
in cultures treated with blebbistatin. In control cultures, SC dis-

played abundant cortical actin and stress fibers (Fig. 3 A), where
myosin light chain (MLC) staining was also found (Fig. 3 B,
inset 1). Staining for the cell adhesion molecule N-cadherin, a
protein thought to mediate the initial growth of SC processes and
their alignment with axons (Wanner and Wood, 2002), was enriched at membrane protrusions (Fig. 3 B), together with ERM (not
depicted). In randomly polarized (front-to-back) SC, N-cadherin
was concentrated at the leading edge protrusions and also at the
tip of the cell tail (Fig. 3 B, inset 2). MLC staining was also enriched at the retracting tail (Fig. 3 B, inset 2), where it colocalized
with vinculin (Fig. 3, inset 4), a marker of focal adhesions (Fig. 3 B,
inset 3). Treatment with blebbistatin (15–60 min) resulted in striking changes in the organization of the actin cytoskeleton (Fig. 3 C).
Changes included loss of stress fibers and the formation of multiple actin spikes and ruffling lamellipodia throughout the entire
cell body (Fig. 3 C and Video 1, available at http://www.jcb
.org/cgi/content/full/jcb.200802091/DC1); N-cadherin and ERM
were highly concentrated at these sites (Fig. 3 D, arrowheads).
REGULATION OF MYELINATION BY MYOSIN II • Wang et al.
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Figure 4. Myosin II inhibition in oligodendrocyte-DRG cocultures enhances myelin formation. (A) Puriﬁed OL progenitors (OPC) were seeded onto 3-wk-old
DRG neuronal cultures. After 2 wk in media containing 1 μg/ml TrkA-Fc, cultures were stained for Olig2, MBP, and neuroﬁlament. Treatment with blebbistatin resulted in a prominent dose-dependant increase in the amount of myelin segments formed in cultures. (B) Quantitation of myelin segments (left),
OL cell number (middle), and MBP expression (right) in control and blebbistatin-treated cultures. A signiﬁcant dose-dependent increase in the amount of
MBP+ segments was observed in cultures treated with blebbistatin (P < 0.001, ANOVA). The percentage of MBP+ cells is comparable in all conditions, and
at the highest blebbistatin concentration (25 μM), a signiﬁcant reduction in the number of Olig2+ cells was observed. Data represent mean ± SEM from
two independent experiments (two cultures per condition per experiment). (C, left) Quantitation of the number of myelin segments formed per single OL in
cultures. Low-density 16-d-old myelinating cocultures were stained for Olig2, MBP, and neuroﬁlament to identify individual OL nuclei, OL expressing MBP,
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Many long and very thin dendrite-like processes were also observed in treated cultures (Fig. 3 B, asterisks).
Because perturbation of N-cadherin function in SC-DRG
cocultures also results in multipolar SC that do not align with
axons (Wanner and Wood, 2002), we next examined the distribution of N-cadherin in premyelinating SC-DRG cocultures treated
with blebbistatin. As described previously (Wanner and Wood,
2002), accumulation of N-cadherin in a “track-like” staining pattern was observed along the SC–axon interface in control cultures (Fig. 3, E and F). This distribution was dramatically affected
by blebbistatin treatment, as multipolar SC extended many
N-cadherin–positive processes toward different axons (Fig. 3,
G and H). The pattern for N-cadherin staining along these processes was different from that observed in control cultures (Fig. 3,
E and F), and although some patchy accumulation was observed
at points of SC–axon contact, they were not restricted to these
sites but were also found in processes that did not contact axons
(Fig. 3, G and H). Thus, our data suggest that myosin II in SC
restricts actin protrusive activity, which in turn is important to
establish SC polarity and proper contact with the axon.
Myosin II inhibition in OL-DRG cocultures
enhances myelin formation

We next examined whether myosin II was also required for central myelination. To this end, cocultures of DRG neurons and
purified rat cortical OL precursor cells (OPC) were grown for
2 wk in myelination-promoting conditions with or without blebbistatin. Cultures were then stained for Olig2, MBP, and neurofilament to identify individual OL nuclei, OL expressing MBP,
and those actively myelinating axons. In striking contrast to SC
myelination, inhibition of myosin II activity by blebbistatin resulted in a prominent increase in the amount of myelin formed
in DRG-OL cocultures (Fig. 4 A). Quantitation of the number
of MBP+ segments showed a significant dose-dependent increase (P < 0.001, analysis of variance [ANOVA]) in the amount
of MBP+ segments in cultures treated with blebbistatin (Fig. 4 B).
Interestingly, despite the difference in the total number of myelin segments, we found that differentiation of OL as measured
by MBP expression (Fig. 4 B) was comparable between control
and treated cultures (ⵑ70–80% MBP+ cells). Furthermore, at
the highest blebbistatin concentration tested (25 μM), a significant decrease in proliferation (Table S1) and in the total number
of Olig2+ cells was consistently observed, yet these cultures
had, on average, more myelinated segments per field than control cultures (P < 0.001). These results strongly suggest that in
blebbistatin-treated cultures, individual myelinating OL give
rise to more internodes than OL in control cultures. To facilitate
the quantitation of the number of internodes made by a single
myelinating OL, we established cocultures with a lower number
of OPC (50,000 instead of 100,000). As anticipated, the mean
number of myelin segments made by a single OL in blebbistatin-treated cultures was 3–4 times more than OL in control
cultures (control, 4.8 ± 3.5; 10 μM blebbistatin, 14.6 ± 5.5; 25 μm

blebbistatin, 18.5 ± 9.3; mean ± SEM; P < 0.001; Fig. 4 C).
Collectively, these results indicate that myosin II activity is not
required for OL differentiation and myelination, and that in the
presence of blebbistatin, individual OL are more branched and
make more myelin.
Knockdown of myosin II in
OL-DRG cocultures by shRNA
enhances myelin formation

To further investigate the contribution of OL myosin II on myelin formation, we infected OPC-DRG cocultures with shRNA
lentivirus against the regulatory chain of MLC. Lentiviral infection of purified OPC cultures resulted in significant cell death
(unpublished data), whereas infection of OPC in cocultures with
DRG neurons was well tolerated. Incubation of cocultures with
lentivirus resulted in the preferential infection of OPC rather
than neurons, as indicated by GFP expression (Fig. S3, available
at http://www.jcb.org/cgi/content/full/jcb.200802091/DC1). As
a further control, we infected established DRG cultures with the
lentivirus for several days before adding OPC and inducing myelination. As shown in Fig. 5, knockdown of MLC in OPC-DRG
cocultures also resulted in a significant increase (P < 0.001) in
myelination similar to that observed in cultures treated with
blebbistatin. Myelination in the presence of nontargeting lentivirus (shSCR) or vector alone was comparable to that observed
in nontreated control cultures. In addition, myelination of neurons
preinfected with lentivirus was comparable to controls (unpublished data), which further indicates that enhanced myelination
results from the specific inhibition of myosin II in OL.
Inhibition of myosin II increases the
complexity of OL branching in cultures

To further characterize the effects of myosin II inhibition on
OL, we measured the effects of blebbistatin treatment on proliferation, survival, and differentiation of purified OPC cultures.
In contrast to OPC in coculture with neurons, where we found a
decrease in proliferation at the highest drug dose (Table S1),
blebbistatin had no significant effect on the proliferation of purified OPC maintained for 3 d in media containing PDGF and
basic FGF (bFGF; 35.6 ± 1.3% [control] vs. 35 ± 1.1% [25 μM
blebbistatin]; mean percentage BrdU ± SEM; P > 0.05). Staining for caspase 3 revealed a slight increase in the percentage of
apoptotic cells in blebbistatin-treated cultures; however, this
difference was not statistically significant (3.3 ± 0.4% [control]
vs. 4.6 ± 0.7% [25 μM blebbistatin]; mean ± SEM, P > 0.05).
Thus, we concluded that inhibition of myosin II did not have a
significant impact on OPC proliferation and survival.
To evaluate differentiation, OPC cultures were kept for 3 d
in media supplemented with T3 with or without blebbistatin and
then stained for MBP expression. Unlike OPC in coculture with
neurons, we found a modest but significant increase in the percentage of cells expressing MBP in blebbistatin-treated cultures compared with control (40 ± 1.7% [control] vs. 49 ± 2%

and OL actively myelinating axons. A signiﬁcant increase in the mean number of myelin segments made by a single OL in treated cultures was observed
(P < 0.001, ANOVA). Data represent mean ± SEM from two independent experiments (two cultures per condition per experiment). (right) Representative
examples of myelinating OL in control and treated cultures are shown. Bars: (A) 50 μm; (C) 20 μm.
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Figure 5. Knockdown of myosin II in OLDRG cocultures enhances myelin formation.
(A) 3-wk-old myelinating OL-DRG cocultures
stained for MBP, Olig2, and neuroﬁlament.
Cocultures were infected with a lentiviral vector expressing shRNA against the regulatory
chain of myosin II (shMLC) or nontargeting
scrambled sequence (shSCR). Knockdown of
MLC in OPC-DRG cocultures resulted in a signiﬁcant increase in myelination similar to that
observed in cultures treated with blebbistatin.
Myelination in control cultures infected with
vector alone or in cultures where neurons were
preinfected with lentivirus was comparable to
that observed in nontreated control culture (not
depicted). Bars, 50 μm. (B) Quantitation of
MBP+ segments per ﬁeld. Data represent mean ±
SEM from two independent experiments (three
cultures per condition per experiment).

[treated]; mean ± SEM; P < 0.005; Fig. 6 A). OL in the blebbistatin-treated group also exhibit extensive membrane expansion
(Fig. 6 A), a change that has been correlated with myelin sheath
formation (Kachar et al., 1986; Kim et al., 2006; Sloane and
Vartanian, 2007). We next examined the effects of blebbistatin
treatment in OL morphological complexity and branching. We
measured the fractal dimension of individual OL in control and
blebbistatin-treated cultures. An increase in fractal dimension
has been correlated with OL maturation in culture (Behar, 2001).
We found that treatment with blebbistatin significantly increased
the mean fractal dimension of OL in cultures (1.37 ± 0.12 [control] vs. 1.46 ± 0.08 [treated] mean ± SEM; P < 0.001; Fig. 6 B),
which indicates more complex cytoskeleton branching in the
absence of myosin II activity. Real-time studies also revealed a
dramatic increase in protrusive activity along the OPC cell body
and branches, with extensive formation of filopodia and ruffling
lamellipodia. We also observed the development of new branches
within 15–30 min of treatment with blebbistatin via the coalescence of some of these processes (Videos 2 and 3, available at
http://www.jcb.org/cgi/content/full/jcb.200802091/DC1). These
results suggest that myosin II inhibition influences OL morphogenesis by promoting complex branching and lamella formation, changes that have been correlated with myelin formation
in vitro (Kachar et al., 1986) and in vivo (Kim et al., 2006;
Sloane and Vartanian, 2007).
Myosin II expression is down-regulated
during OPC maturation in vitro and in vivo

We next examined whether the levels of myosin II protein expression change as OL mature in culture. Cell lysates were prepared from purified OPC cultures kept in proliferating media
(PDGF + bFGF) for 3 d or differentiating media (T3) for 2–7 d.
As shown in Fig. 6 C, levels of myosin IIB (the main isoform
found in OPC and brain) are high when OPC are maintained as
proliferating progenitors. When cultures are switched to differ1178
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entiating media and increase their MBP expression, the levels
of myosin IIB are strikingly down-regulated. Staining of OPC
cultures similarly showed that myosin II is expressed at high
levels in OPC before their differentiation and MBP expression
(Fig. S4, available at http://www.jcb.org/cgi/content/full/jcb
.200802091/DC1). In vivo, myosin II and phosphorylated MLC2
are also down-regulated before myelination, as indicated by Western blots of rat brains collected at different developmental stages
(Fig. 6 D). Because myosin II is a known regulator of actin
bundle turnover (Guha et al., 2005; Medeiros et al., 2006), we
examined whether down-regulation of myosin II correlates with
changes in the expression of proteins involved in promoting actin polymerization and branching. As shown in Fig. 6 D, the
expression levels of WAVE and neuronal Wiskott-Aldrich syndrome protein (N-WASP) were increased at the onset of MBP
expression in OPC and brain extracts, in accordance with their
proposed role in myelin formation (Kim et al., 2006; Bacon
et al., 2007). In contrast, the levels of total actin and Arp2/3
remained unchanged, whereas the levels of phosphorylated (inactive) cofilin were down-regulated, which is consistent with the
role of the nonphosphorylated (active) form in promoting actin
polymerization (Huang et al., 2006). Collectively, these results
suggest that down-regulation of myosin II activity is part of the
“default” differentiation program of OL in vitro and in vivo and
might play a role in promoting actin polymerization at the onset
of myelination.

Discussion
In this study, we have shown that myosin II differentially regulates myelin formation by SC and OL (Fig. 7). Myosin II activity is required for proper interactions between SC and axons, and
its inhibition or down-regulation impairs the ability of SC to
segregate axons and elongate along them, preventing the formation of a 1:1 relationship, which is critical for their differentiation

Figure 6. Blebbistatin promotes OPC differentiation in vitro and increases the complexity of OL branching in cultures. (A) Puriﬁed OPC kept for 3 d
in differentiation-promoting media in the absence or presence of 10 μM blebbistatin. Staining for MBP revealed a slight but signiﬁcant increase in the
percentage of MBP+ cells in myosin II–inhibited cultures. Examples of OL exhibiting extensive membrane expansion are indicated (arrowhead). Data in
graph represent the mean ± SEM of four independent experiments (two cultures per condition per experiment). Bar, 20 μm. (B) Fractal analysis of OPC
morphological complexity was performed in cultures kept for 3 d in differentiation-promoting media in the absence or presence of 10 μM blebbistatin. The
mean fractal dimension (D) in blebbistatin-treated cultures was signiﬁcantly higher than control (1.37 ± 0.12 [control] vs. 1.46 ± 0.08 [treated]; mean ±
SD; P < 0.0001; t test), which indicates more complex cytoskeleton branching in the absence of myosin II activity. Representative examples of low- and
high-complexity OPC stained with O4 are shown on the right. Bars, 10 μm. (C) Western blot of OPC cultures kept in proliferating media (PDGF) for 3 d or
differentiating media (T3) for 2–7 d. A signiﬁcant reduction in the levels of myosin II (isoforms A and B) was found between cultures kept in proliferating
conditions compared with T3. As OPC differentiate, the levels of myosin II are further down-regulated. (D) Developmental expression proﬁle of myosin II,
actin-binding proteins, and MBP in rat brain lysates. The levels of myosin IIB and the phosphorylated regulatory chain (pMLC2) are down-regulated as myelination progresses in rat CNS, whereas total MLC2 remain unchanged. Total actin and Arp2 also remain constant, but the levels of WAVE1 and N-WASP,
proteins that are involved in actin polymerization, are up-regulated at the onset of myelination (P15). In addition, the levels of p-coﬁlin are down-regulated
at this stage, which is consistent with the role of the nonphosphorylated form in promoting actin polymerization.
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Figure 7. Summary of myosin II inhibition effects on myelination by SC
and OL. Myosin II is an important regulator of SC cytoskeleton during differentiation and myelination. Myosin II appears to be necessary for the
establishment of SC polarity and elongation along the axons, a crucial step
in the initiation of myelin formation in the PNS. In the absence of myosin II
activity, SC are unable to segregate axons in a 1:1 relationship and myelinate. In contrast, OL differentiation and myelin formation are independent
of myosin II activity. Furthermore, down-regulation of myosin II promotes
actin polymerization and branching, and also results in a signiﬁcant increase in the amount of myelinated segments formed in culture.

and myelination. In contrast, OL branching and myelin formation are potentiated by inhibition or down-regulation of myosin II.
Thus, by controlling the spatial and localized activation of actin
polymerization, myosin II regulates SC polarization along
the axon and OL branching, and thereby their ability to form
myelin. These results indicate that the mechanisms regulating
myelin formation in the PNS and CNS are distinct.
Myosin II is a key regulator of SC
cytoskeleton polarity, differentiation,
and myelination

We have presented evidence that myosin II activity is an important regulator of SC cytoskeleton organization during differentiation and myelination. SC lacking myosin II activity exhibit a
multipolar morphology, with round nuclei and multiple long
processes that fail to elongate properly along the axons and
myelinate. Multipolar morphology is also observed in myosin II–
null fibroblasts (Lo et al., 2004; Even-Ram et al., 2007), which
are unable to move in a directed and persistent manner. Thus,
the failure to segregate and eventually myelinate the axons they
contact might be partly explained by the inability of multipolar
SC to orient their cytoskeleton and move in a directed manner,
following cues from the axon and the ECM. EM analysis
corroborated these observations, demonstrating that in myosin
II–inhibited cocultures, SC associate with but fail to completely
ensheath axons. Similarly, expression of myelin-specific proteins
and transcription factors, and the amount of myelin formed in
myosin II–inhibited cocultures, was greatly reduced. In agreement with these results, disruption of actin polymerization by
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cytochalasin D inhibits SC elongation, myelin-specific mRNA
expression, and myelination (Fernandez-Valle et al., 1997). Likewise, defects in SC polarity, regulation of actin-protrusive activity, and axon alignment have been shown in merlin-deficient
Schwannoma cells and are thought to be involved in the process
of dedifferentiation of these tumor cells (Nakai et al., 2006;
Flaiz et al., 2007).
We postulate that, akin to its role in epithelial cells, myosin II plays a key role in SC polarity in regulating the formation,
localization, and spreading of cell–cell contacts between SC
processes and axons. Myosin II–mediated contractility controls
the accumulation of adhesion complexes and the establishment
of epithelial cell polarity (Ivanov et al., 2005; Miyake et al., 2006)
and also helps to maintain adhesion and cadherin accumulation
at the apical border of epithelial cells (Shewan et al., 2005;
Ma et al., 2007).
These observations are likely to be relevant to the initial
interactions between SC and axons, as during their development,
SC acquire a distinct polarity with an adaxonal region contacting
the axon and abaxonal surface in contact with the basal lamina
(Bunge and Bunge, 1986). As for epithelial cell function, the development of this polarity is essential for SC differentiation and
myelination and also plays a key role in establishing the different
functional domains of myelinated axons (Salzer, 2003).
The initial contact and alignment of SC processes with the
axons they myelinate is mediated by the accumulation of celladhesion molecules such as N-cadherin along the SC–axon interface (Wanner and Wood, 2002), where it colocalizes with the
polarity protein Par-3 (Chan et al., 2006). We have found that
myosin II inhibition perturbs N-cadherin accumulation at sites
of SC–axon contact and results in a multipolar SC that is unable
to align along the axons, which is similar to that resulting from
disrupting N-cadherin function (Wanner and Wood, 2002). Thus,
loss of actomyosin contractility and delocalized accumulation
of cell adhesion complexes might in part explain the effects in
SC morphology and differentiation caused by the inhibition or
down-regulation of myosin II activity.
Down-regulation of myosin II activity
promotes actin polymerization,
oligodendrocyte branching,
and myelin formation

In contrast to SC, terminal differentiation of OL is paradoxically promoted in the absence of myosin II activity. Thus, the
percentage of OPC expressing MBP, the complexity of OL branching, and the amount of myelin segments formed in culture by
individual cells are all increased. These results indicate that
myosin II activity modulates key aspects of OL morphogenesis
and myelination. In potential agreement, there is an inverse correlation between the levels of MBP and myosin II expression,
which suggests that down-regulation of myosin II activity may
be an obligate component of the differentiation program of OPC
in vitro and in vivo. Interestingly, recent functional genomics
studies have shown that Myh10, the heavy chain of nonmuscle
myosin IIB, is enriched in acutely purified OPC and is similarly
down-regulated during OL terminal differentiation (Dugas et al.,
2007; Cahoy et al., 2008).

OPC in culture differentiate progressively through a sequence of stages characterized by distinct morphologies and
expression of specific markers (Pfeiffer et al., 1993). As OPC
mature and form lamella, the complexity and branching of their
cytoskeleton increases (Behar, 2001). These cytoskeletal changes
have been linked to OL differentiation and myelin formation in
vitro and in vivo (Kachar et al., 1986; Kim et al., 2006; Sloane
and Vartanian, 2007). The importance of the actin cytoskeleton
during these events is highlighted by the myelination deficits
exhibited by mice deficient for WAVE-1, an actin-associated
protein important for lamellipodia formation (Kim et al., 2006).
In vitro, OPC from WAVE1-null mice have fewer processes and
defective lamella formation, and also exhibit regional CNS
hypomyelination (Kim et al., 2006).
In the present study, we identify an inverse correlation between myosin II activity and OPC branching and myelination.
Thus, in OPC cultures, down-regulation of myosin II appears to
promote actin polymerization and branching, changes that translate into more myelin segments formed in culture by individual
OPC. Although the direct role of myosin II in actin turnover is
still not well understood, recent in vitro studies have shown that
myosin II can act as an actin-depolymerizing agent (Haviv et al.,
2008), and that at high myosin II concentrations, the formation
and growth of actin filament bundles is inhibited. This study also
found that in the presence of blebbistatin, the density of actin filaments is higher, suggesting that “inactive motors” act as passive
actin cross-linkers (Haviv et al., 2008). Of note, a similar role for
myosin II as a negative regulator of actin polymerization during
growth cone development and consolidation has been described
previously (Medeiros et al., 2006). As the distal tips of OL processes resemble growth cones in their behavior and molecular
composition (Fox et al., 2006), myosin II may have a similar role
in regulating the actin cytoskeleton in both structures.
Regulation of myosin II activity during
myelin formation

The mechanisms that regulate myosin II activity in SC and OL
during myelination are not yet known. In SC, phosphorylation
of the regulatory chain of myosin II (MLC2) is up-regulated at
the onset of myelination and then down-regulated (MelendezVasquez et al., 2004), following the same pattern of Rho activation in peripheral nerve extracts (unpublished data). Our previous
studies revealed an important role for ROCK during the initial
events of PNS myelination, possibly by regulating the phosphorylation status of MLC (Melendez-Vasquez et al., 2004). However, inhibition of ROCK did not interfere with the wrapping of
the axon, which suggests that another ROCK-independent mechanism controls the actual motor of SC adaxonal membrane progression around the axon. Our current study extends these initial
observations and provides further evidence of the important role
of polarized actomyosin contraction for SC myelin formation.
Similar to our previous results with a ROCK-specific pharmacological inhibitor, the effects of myosin II inactivation on SC myelination are more marked when the inhibition occurs at the
early stages of myelin formation, with little effect on older cultures. This early requirement for ROCK and myosin II activity
at the onset of myelination appears to be important for the sup-

pression of SC branching and the establishment of proper cell
polarity (Melendez-Vasquez et al., 2004). However, unlike inhibition of ROCK-mediated MLC phosphorylation, which promotes
the coordinated wrapping of the axon, inhibition of myosin II
ATPase activity by blebbistatin or down-regulation of myosin II
total levels by shRNA completely blocked myelin formation.
These contrasting effects provide compelling evidence for the
existence of different mechanisms controlling myosin II activity
within the SC, as has been demonstrated in other cell types
(Totsukawa et al., 2000, 2004).
In OL, constitutive activation of Rho interferes with OL
branching and maturation (Wolf et al., 2001; Liang et al., 2004).
Although direct proof is lacking, inactivation of Rho might affect myosin II activity in OL via down-regulation of ROCK activity and, hence, MLC phosphorylation. Our results showing
that the expression levels of phosphorylated MLC by OPC are
higher before MBP up-regulation both in vivo and in vitro and
that down-regulation of myosin II levels and activity promotes
myelination are consistent with this model. Interestingly, phosphorylation of myosin II by ROCK has been identified as a negative regulator of F-actin polymerization in developing growth
cones (Loudon et al., 2006), providing a possible mechanism
for the regulation of OL branching and differentiation via the
Rho–ROCK–myosin II pathway.
Myosin II has three isoforms, IIA, IIB, and IIC, which are
differentially localized and regulated in many cell types and that
appear to have different functions during cell migration and
spreading (Conti and Adelstein, 2008). We have found that SC
express all three isoforms, although in cocultures, myosin IIB
predominates over IIA and IIC at the initial stages of axon–SC
contact, whereas IIC is up-regulated in myelinating SC (unpublished data). In SC-only cultures, myosin IIB and MLC staining
are colocalized at the tip of the retracting tail, in stress fibers, and
at the leading edge of polarized cells (Fig. 3 and not depicted).
OL also express all three myosin II isoforms. Myosin IIB is the
main isoform detected in OPC in vitro and in vivo during early
development, whereas myosin IIC, which is not detected at early
stages, predominates in differentiated OL (Cahoy et al., 2008) and
in adult brain (Golomb et al., 2004). Myosin IIB is also the predominant isoform expressed at the leading edge of OL processes
together with actin (Song et al., 2001), making it a good candidate
to mediate the effects of myosin II inhibition on OL myelination.
In agreement with this idea, we have found that siRNA knockdown of myosin IIB in OPC has the same effect on OL myelination as MLC2/myosin II down-regulation (unpublished data).
Collectively, these data suggest that differential spatial
regulation of myosin II isoforms by various kinases or the GTPases
that in turn control these enzymes might play a key role in myelination. Of note, activation of Rac-GTPase downstream of
␤1-integrin has been shown to play an important role in SC process extension, axonal sorting, and myelination (Benninger
et al., 2007; Nodari et al., 2007). Because delocalized activation
of Rac and membrane ruffling in myosin II–null fibroblasts has
been shown to cause defects in polarized cell migration (Even-Ram
et al., 2007), it will be of interest to determine the activation
status of myosin II in the nerves of conditional ␤1-integrin or
Rac knockout mice.
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Myelination in the CNS and PNS is
differentially regulated by myosin II

Although SC and OL have a conserved function as myelinforming cells, they differ in developmental origin (Jessen and
Mirsky, 2005; Richardson et al., 2006) and key aspects of their
cell biology, including their response to axon-derived signals
during terminal differentiation and myelination (Stevens et al.,
1998, 2002; Chan et al., 2004; Taveggia et al., 2005, 2008) and
the different patterns of association with the axons they myelinate. Thus, SC and OL initially extend processes and associate
with several axons, but whereas a single OL can wrap up to 40
axons simultaneously, individual SC will ultimately segregate
and myelinate only one axon. Central myelinated axons also
lack the basal lamina characteristic of SC myelination. In this
study, we have shown that by controlling SC polarization along
the axon and promoting OL branching, myosin II differentially
regulates their ability to form myelin. Our findings provide a
novel conceptual framework for how the different patterns of
SC and OL myelination are established and indicate that the
mechanisms regulating glial cell differentiation and myelination in the PNS and CNS are fundamentally different. Further
studies on the signals that regulate myosin II activity in SC and
OL should help to clarify its role during myelin formation.

Materials and methods
Myelinating SC-DRG cocultures
DRG neurons were isolated from embryonic day 16 rat spinal cords and
either trypsinized or directly plated as explants on collagen-coated coverslips (BD Biosciences). Cultures were maintained in serum-free neurobasal
medium (NB medium; 2% B27 supplement, 2 mM L-glutamine, 0.4% glucose, and 50 ng/ml 2.5S NGF). Nonneuronal cells were removed by
feeding the cultures with NB medium containing 5-ﬂuorodeoxyuridine and
uridine. SC were isolated from postnatal day 2 sciatic nerves and expanded for ⵑ3 wk in D media (DME, 10% FBS, and 2 mM L-glutamine)
supplemented with 4 μM forskolin and 5 ng/ml of the EGF domain of
rhNRG-1-␤1 (R&D Systems). Myelinating cocultures were established by
seeding puriﬁed DRG neuron cultures with 100,000 SC in C media (MEM,
10% FBS, 2 mM L-glutamine, 0.4% glucose, and 50 ng/ml 2.5S NGF).
After 3 d, cocultures were changed to media supplemented with 50 μg/ml
ascorbic acid to initiate basal lamina formation and myelination. For studies of the effects of myosin II inhibition on myelination, cocultures were
switched to myelin-promoting media containing blebbistatin (EMD). Control and treated cultures were allowed to myelinate for 2–3 wk, with fresh
media provided every 2–3 d. To determine the extent of myelination in
SC-DRG cocultures, the total number and length of MBP+ segments were
counted in micrographs from 10–12 random low-power ﬁelds per coverslip using ImageJ version 1.38 (total of 20–24 ﬁelds per condition per experiment; total of 2–3 experiments). Statistical tests (t test and ANOVA)
were performed using GraphPad Prism (GraphPad Software).
Puriﬁed OPC cultures and OPC-DRG myelinating cocultures
Primary OL precursors (OPC and A2B5+) were puriﬁed by immunopanning
from mixed glial cultures of postnatal day 1 rat cerebral cortices as described previously (Taveggia et al., 2008). Puriﬁed OPC were seeded onto
poly-lysine–coated glass coverslips and maintained in Sato media (DME,
100 μg/ml transferrin, 100 μg/ml BSA, 20 nM progesterone, 100 μM putrescine, 30 nM sodium selenite, 2 mM L-glutamine, 5 μg/ml insulin, 60 μg/ml
N-acetyl cysteine, and 10 μM forskolin) with 10 ng/ml PDGF and 10 ng/ml
bFGF for proliferation or induced to differentiate in Sato containing T3
(30 ng/ml). DRG explants were isolated from rat embryonic day 16 spinal
cords and plated directly onto glass coverslips coated with Matrigel (BD
Biosciences). Explants were kept in NB medium and treated with antimitotic
agents to eliminate nonneuronal cells. Explants were allowed to extend a
dense neurite network for at least 2–3 wk before their use in coculture experiments. OPC-DRG cocultures were established as described previously (Chan
et al., 2004). In brief, freshly puriﬁed OPC (50,000–100,000 cells) were
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seeded directly onto DRG explants in MEM media containing 10% FBS,
2 mM L-glutamine, and 0.4% glucose. Myelination was induced the following
day by addition of 1 μg/ml TrkA-Fc (R&D Systems). For studies of the effects
of myosin II inhibition on myelination, blebbistatin (EMD) was also added to
the media at this point and maintained throughout the experiment. Cultures
were allowed to myelinate up to 18 d, with fresh media provided every 2–3 d.
Myelin segments were identiﬁed by MBP and neuroﬁlament staining, then
counted in micrographs from 8–10 random low-power ﬁelds per coverslip
using ImageJ version 1.38 (total of 16–20 ﬁelds per condition per experiment; total of 2–3 experiments). Statistical tests (t test and ANOVA) were
performed using GraphPad Prism software.
RNAi of myosin II in puriﬁed glia and myelinating cocultures
To generate shRNAs, we used the pLentiLox (pLL3.7) vector (provided by
L. Van Parijs, Massachusetts Institute of Technology, Cambridge, MA; Rubinson
et al., 2003). Two 19-nucleotide shRNAs (MLC1, 5⬘-GCACGGAGCGAAAGACAAA-3⬘; and MLC2, 5⬘-GAGGCCTTCAACATGATCG-3⬘) targeting
the regulatory (light) chain of rat myosin II (MLC) were designed using Easy
siRNA (ProteinLounge). The 5⬘-phosphorylated PAGE-puriﬁed oligonucleotides were annealed and subcloned into HpaI–XhoI sites of pLL3.7. The
lentiviral vector was transfected into 293FT cells together with packaging
plasmids ⌬8.9 and pCMV-VSVG (provided by J. Milbrandt, Washington
University, St. Louis, MO) using Lipofectamine 2000 (Invitrogen). As control,
we used the empty pLL3.7 vector or a vector encoding shRNA to a nontargeting (scrambled) sequence. Viral supernatants were collected 72 h after transfection, centrifuged at 3,000 rpm for 15 min, aliquoted for one-time use, and
frozen at ⫺80°C. Freshly plated SC were incubated for 3 d with viruses at a
2:3 dilution (vol/vol) in D media (DME, 10% FBS, and 2 mM L-glutamine)
supplemented with forskolin and rhNRG-␤1 (EGF domain). Cells were expanded for an additional week and maintained for 3 d in D media before
use for myelination experiments. Protein knockdowns were conﬁrmed by
Western blotting. For shRNA knockdown experiments in OPC-DRG cocultures, cultures were incubated with lentivirus supernatant at 1:3 dilution for 2 d.
The virus was removed and cultures were allowed to myelinate for an additional 2 wk. This protocol resulted in the effective infection of OPC over
neurons. As a control, we used established DRG cultures that were infected
with the virus before adding the OPC and inducing myelination.
Antibodies
Antibodies used in these studies included those reactive to: MBP (SMI-94)
and neuroﬁlament (SMI-31 and SMI-32; Sternberger Monoclonals); myosin
IIA and IIB (Covance), coﬁlin, phosphorylated coﬁlin, MLC2, phosphorylated MLC2, phosphorylated FAK, Arp2, and vinculin (Cell Signaling
Technology); phalloidin-FITC, phalloidin-coumarin, rabbit anti-EHS laminin, anti–caspase 3, and anti-actin (Sigma-Aldrich); anti-GFP, WAVE-1,
and Olig2 (Millipore); anti–N-WASP (H100; Santa Cruz Biotechnology,
Inc.); anti–N-cadherin and anti-Tau (BD Biosciences). Polyclonal antibodies to Krox-20 and Oct-6 (provided by D. Meijer, Erasmus University,
Rotterdam, Netherlands), P0 (M. Filbin, Hunter College, City University of
New York, New York, NY), laminin ␣-2 chain (P. Yurchenco, Robert
Wood Johnson Medical School, University of Medicine and Dentistry of
New Jersey, Piscataway, NJ) and myelin-associated glycoprotein were
also used. Mouse A2B5 and Ran-2 hybridomas were obtained from the
American Type Culture Collection. Mouse O4 was a gift from M. Chao
(New York University, New York, NY). Secondary antibodies conjugated
to rhodamine, ﬂuorescein, coumarin, or cyanin 5 were obtained from
Jackson ImmunoResearch Laboratories.
Immunoﬂuorescence
Cultures (SC, OPC, and myelinating cocultures) were ﬁxed in 4% PFA and
processed for immunocytochemistry as described previously (MelendezVasquez et al., 2004). For surface antigen staining (A2B5 and O4), cells
were blocked with 1% donkey serum and 5% BSA in PBS for 30 min, then
incubated with primary antibody as described previously (Zhang et al.,
2006). Cultures were examined by epiﬂuorescence or confocal microscopy (see the following paragraph).
Image acquisition and analysis
Epiﬂuorescence images were acquired using a microscope (DMI 4000B;
Leica) with LAS 1.7.0 software equipped with a digital camera (DFC350FX;
Leica) and the following objectives: N PLAN 10×/0.25 NA; N PLAN L
40×/0.55 NA; and HCX PL APO CS 63×/1.4 NA oil UV (all from Leica).
Confocal images were acquired with a laser scanning microscope (LSM
510; Carl Zeiss, Inc.) using Plan-Apochromat 20×/0.75 NA or Neoﬂuor
40×/1.3 NA oil objectives and LSM software (all from Carl Zeiss, Inc.).
Image processing and quantitation (including fractal analysis) was performed

using ImageJ version 1.38 and Photoshop CS8 (Adobe). Adjustment of image brightness or contrast was performed in some cases but without misrepresenting data.
Time-lapse microscopy
Videos were acquired with a DMI 4000B microscope system (see the previous section) ﬁtted with a stage incubator and a temperature and CO2 digital
controller (CTI Controller 37000; Pecon). Cells were plated on poly-lysine–coated glass-bottomed 35-mm tissue culture dishes (MatTek) on D media
(SC) or proliferating OPC media. Phase images from SC and OPC cultures
were acquired for a period of 15–30 min using an N PLAN L 40×/0.55
NA objective. Cultures were maintained at 37°C and 5% CO2 throughout
the observation period.
Proliferation and survival assays
To investigate the effect of myosin II inhibition on the proliferation and cell
survival of SC and OPC, BrdU incorporation (Boehringer Mannheim Gmbh)
and TUNEL assays (Promega) were performed according to manufacturers’
instructions as described previously (Melendez-Vasquez et al., 2004;
Zhang et al., 2006).
Cell extracts and Western blotting
Lysates from rat tissues (brain and nerves), cultures of SC, OPC, and myelinating cocultures were prepared as described previously (Melendez-Vasquez
et al., 2004), subjected to SDS-PAGE, and blotted onto nitrocellulose. Appropriate regions of the blots were cut and incubated with speciﬁc antibodies
and developed using chemiluminescent substrate (Thermo Fisher Scientiﬁc).
Electron microscopy
Control and treated myelinating cocultures were rinsed in PBS, ﬁxed overnight at 4°C in 2% glutaraldehyde in 0.1 M phosphate buffer, pH 7.0, and
processed further as described previously (Einheber et al., 1995). Specimens
were examined on an electron microscope (CM10; Philips).
Online supplemental material
Fig. S1 shows changes in SC morphology after blebbistatin treatment in
cocultures. Fig. S2 shows an example of SC forming multiple short internodes in blebbistatin-treated cultures. Fig. S3 shows preferential infection
of OPC by lentivirus in cocultures. Fig. S4 shows expression of phosphorylated MLC during OPC differentiation in vitro. Table S1 shows the quantitation of BrdU incorporation in PNS and CNS myelinating cocultures. Video 1
shows formation of rufﬂing lamellipodia in SC after blebbistatin treatment.
Videos 2 and 3 show actin-protrusive activity of an OPC before and after
treatment with blebbistatin. Online supplemental material is available at
http://www.jcb.org/cgi/content/full/jcb.200802091/DC1.
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